Future studies will examine the contribution of RalA-dependent and RalA-independent signaling pathways in Rgl2-induced activation of the PI3K/Akt signaling cascade, and whether Rgl2 represents a novel therapeutic target in cardiac disease. The gene discussed is AKT1; the disease is heart disorder.